XML 49 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Legal Proceedings, Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Litigation Settlement

The litigation settlements are summarized as follows (in thousands):

 

     Amount  

Class action settlement in 2015

    $ 20,000  

Derivative settlement in 2015

      5,000  

Shareholders securities litigation settlements in 2016

      1,800  

SEC settlement in 2016

      950  
  

 

 

  

Total settlements

    $ 27,750  
  

 

 

  

Payable by the Company in cash as of December 31, 2016

    $ 950  

Paid by the insurance carriers in 2016

      21,700  

Paid by the Company in cash in 2016

      2,450  

Paid by the Company in common stock in 2016

      2,650  
  

 

 

  

Total settlements

    $ 27,750  
  

 

 

  

 
Schedule of Contractual Obligations and Future Cash Payments

 The Company’s contractual obligations that may require future cash payments as of December 31, 2016 are as follows (in thousands):

 

     Operating
Leases(1)		      Non-
Cancelable
Employment
Agreements(2)		      Subtotal      Cancelable
License
Agreements(3)		      Total  

2017

    $ 241      $ 1,601      $ 1,842      $ 1,391      $ 3,233  

2018

      246        —          246        350        596  

2019

      251        —          251        350        601  

2020

      236        —          236        7,350        7,586  

2021 and thereafter

      —          —          —          8,815        8,815  
     

 

 

     

 

 

     

 

 

     

 

 

  

Total

    $ 974      $ 1,601      $ 2,575      $ 18,256      $ 20,831  
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

(1)  Operating leases are primarily facility and equipment related obligations with third party vendors. Operating lease expenses during the years ended December 31, 2016, 2015, and 2014 were approximately $291,000, $116,000 and $72,000, respectively.
(2)  Employment agreement obligations include management contracts, as well as scientific advisory board member compensation agreements. Certain agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually at the discretion of the Compensation Committee, as well as for minimum bonuses that are payable.
(3)  License agreements generally relate to the company’s obligations with The Board of Regents, University of Texas M.D. Anderson Cancer Center and the Henry M. Jackson Foundation for our oncology therapies and the obligations with Biovascular Inc. and Mills Pharma for our GALE-401 asset. The company continually assesses the progress of its licensed technology and the progress of its research and development efforts as it relates to its licensed technology and may terminate with notice to the licensor at any time. In the event these licenses are terminated, no amounts will be due.